Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis

Published:2023-04 Issue:4 Volume:9 Page:e14794
ISSN:2405-8440
Container-title:Heliyon
language:en
Short-container-title:Heliyon

Author:

Du Jincheng,Wang Xinyu,Fan Liwen,Shan Xinyuan,Li Muyao,Liu Linlin

Funder

Department of Science and Technology of Jilin Province

Jilin Province Development and Reform Commission

Department of Finance of Jilin Province

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference32 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Pathology of lung cancer;Travis;Clin. Chest Med.,2011

3. Small cell lung cancer: where do we go from here?;Byers;Cancer,2015

4. Cancer statistics;Siegel;CA Cancer J Clin,2022

5. SCLC treatment in the immuno-oncology era: current evidence and unmet needs;Belluomini;Front. Oncol.,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of immunotherapy as first−line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data;Frontiers in Oncology;2024-07-04

2. Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer: a network meta-analysis;Frontiers in Immunology;2024-04-17

3. Serplulimab monotherapy in extensive-stage small-cell lung cancer with brain metastasis: a case report;Immunotherapy;2024-03-27

4. The DC–T cell axis is an effective target for the treatment of non‐small cell lung cancer;Immunity, Inflammation and Disease;2023-11